Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Francisco Gascón‐Giménez"'
Autor:
José E. Meca-Lallana, José M. Prieto González, Ana B. Caminero Rodríguez, Javier Olascoaga Urtaza, Ana M. Alonso, Eduardo Durán Ferreras, Raúl Espinosa, Julio Dotor, Mercedes Romera, Adrián Ares Luque, Domingo Pérez Ruiz, Carmen Calles, Miguel A. Hernández, Miguel Hervás García, Amelia Mendoza Rodríguez, Yasmina Berdei Montero, Nieves Téllez, Nicolás Herrera Varó, Javier Sotoca, Silvia Presas-Rodríguez, Luis A. Querol Gutierrez, Mariona Hervás Pujol, Jordi Batlle Nadal, Gisela Martín Ozaeta, Laura Gubieras Lillo, Sergio Martínez Yélamos, Lluís Ramió-Torrentà, Javier Mallada Frechin, Antonio Belenguer Benavides, Francisco Gascón-Giménez, Bonaventura Casanova, Lamberto Landete Pascual, Leticia Berenguer, Laura Navarro, Montserrat Gómez Gutierrez, Carmen Durán, Ana Rodríguez Regal, Elena Álvarez, Daniel A. García-Estévez, Ana M. López Real, Miguel A. Llaneza González, María E. Marzo Sola, José L. Sánchez-Menoyo, Agustín Oterino, Ramón Villaverde González, Tamara Castillo-Triviño, Amaya Álvarez de Arcaya, Cristina Llarena
Publikováno v:
Neurology and Therapy, Vol 12, Iss 6, Pp 2177-2193 (2023)
Abstract Introduction Teriflunomide is a once-daily oral immunomodulator approved for relapsing forms of multiple sclerosis (MS) or relapsing–remitting multiple sclerosis (RRMS; depending on the local label), based on extensive evidence from clinic
Externí odkaz:
https://doaj.org/article/0d5e12714aa14ddbb6e6eadf49cbbed1
Autor:
Francisco Gascón-Giménez, Carmen Alcalá, Lluís Ramió-Torrentà, Paloma Montero, Jorge Matías-Guiu, Irene Gómez-Estevez, Celia Oreja-Guevara, Sara Gil-Perotín, Yolanda Blanco, María Carcelén, Carlos Quintanilla-Bordás, Lucienne Costa, Luisa Maria Villar, Jose Enrique Martínez-Rodriguez, José Andrés Domínguez, Carmen Calles, Inés González, Javier Sotoca, Agustin Oterino, Celia Lucas-Jimenez, Francisco Pérez-Miralles, Bonaventura Casanova
Publikováno v:
Frontiers in Neurology, Vol 14 (2023)
IntroductionRituximab (RTX) is considered a potential therapeutic option for relapsing-remitting (RRMS) and progressive forms (PMS) of multiple sclerosis (MS). The main objective of this work was to investigate the effectiveness and safety of rituxim
Externí odkaz:
https://doaj.org/article/a88c93d629e84c54ae63a9bf5ae7db28
Autor:
José I. Fernández-Velasco, Enric Monreal, Jens Kuhle, Virginia Meca-Lallana, José Meca-Lallana, Guillermo Izquierdo, Celia Oreja-Guevara, Francisco Gascón-Giménez, Susana Sainz de la Maza, Paulette E. Walo-Delgado, Paloma Lapuente-Suanzes, Aleksandra Maceski, Eulalia Rodríguez-Martín, Ernesto Roldán, Noelia Villarrubia, Albert Saiz, Yolanda Blanco, Carolina Diaz-Pérez, Gabriel Valero-López, Judit Diaz-Diaz, Yolanda Aladro, Luis Brieva, Cristina Íñiguez, Inés González-Suárez, Luis A Rodríguez de Antonio, José M. García-Domínguez, Julia Sabin, Sara Llufriu, Jaime Masjuan, Lucienne Costa-Frossard, Luisa M. Villar
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
ObjectiveTo ascertain the role of inflammation in the response to ocrelizumab in primary-progressive multiple sclerosis (PPMS).MethodsMulticenter prospective study including 69 patients with PPMS who initiated ocrelizumab treatment, classified accord
Externí odkaz:
https://doaj.org/article/c8e040513ca84c5f9b5252521e717dd6
Autor:
Francisco Carlos Pérez‐Miralles, Daniel Prefasi, Antonio García‐Merino, José Ramón Ara, Guillermo Izquierdo, Virginia Meca‐Lallana, Francisco Gascón‐Giménez, María Luisa Martínez‐Ginés, Lluis Ramió‐Torrentà, Lucienne Costa‐Frossard, Óscar Fernández, Sara Moreno‐García, Jorge Maurino, Joan Carreres‐Polo, Bonaventura Casanova
Publikováno v:
Brain and Behavior, Vol 11, Iss 4, Pp n/a-n/a (2021)
Abstract Background and purpose Evidence on regional changes resulting from neurodegenerative processes underlying primary progressive multiple sclerosis (PPMS) is still limited. We assessed brain region volumes and their relationship with disability
Externí odkaz:
https://doaj.org/article/1c68c742d928479ab6b1cd9c261aafe7
Autor:
Angela Vidal-Jordana, Ricardo C Ginestal-López, Virginia Meca-Lallana, Francisco Pérez-Miralles, Joan Carreres-Polo, Francisco Gascón-Giménez, Nieves Téllez-Lara, Yolanda Higueras, Jesús Romero-Imbroda, Sara Eichau-Madueño
Publikováno v:
Scientia
NEUROLOGICAL SCIENCES
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Neurological Sciences
NEUROLOGICAL SCIENCES
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Neurological Sciences
Introduction Cognitive impairment (CI) has a prevalence of 45–70% in people with multiple sclerosis (MS), producing a negative impact on their quality of life, personal life, and work. Early detection of CI has become an important aspect to be cons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fe33d5d261347c786d07f4d2f2ae8ba
https://hdl.handle.net/11351/7681
https://hdl.handle.net/11351/7681
Autor:
Guillermo Izquierdo, Jorge Maurino, Lluís Ramió-Torrentà, Bonaventura Casanova, Daniel Prefasi, Jose R. Ara, Francisco Pérez-Miralles, Lucienne Costa-Frossard, Oscar Fernandez, Virginia Meca-Lallana, Antonio García-Merino, María L Martínez-Ginés, Sara Moreno-García, Francisco Gascón-Giménez, Joan Carreres-Polo
Publikováno v:
Brain and Behavior, Vol 11, Iss 4, Pp n/a-n/a (2021)
Brain and Behavior
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Scientia
Brain and Behavior, 2021, vol.11, núm. 4, p. e02044
Articles publicats (D-CM)
DUGiDocs – Universitat de Girona
Brain and Behavior
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Scientia
Brain and Behavior, 2021, vol.11, núm. 4, p. e02044
Articles publicats (D-CM)
DUGiDocs – Universitat de Girona
Background and purpose Evidence on regional changes resulting from neurodegenerative processes underlying primary progressive multiple sclerosis (PPMS) is still limited. We assessed brain region volumes and their relationship with disability progress
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06d31f4f2b907e3f1fca436a42eb3631
https://doaj.org/article/1c68c742d928479ab6b1cd9c261aafe7
https://doaj.org/article/1c68c742d928479ab6b1cd9c261aafe7
Autor:
Lucienne Costa-Frossard, Guillermo Izquierdo, Francisco Pérez-Miralles, Bonaventura Casanova, Daniel Prefasi, Nicolás Medrano, Jose R. Ara, Oscar Fernandez, Jorge Maurino, Virginia Meca-Lallana, Sara Moreno-García, María L Martínez-Ginés, Francisco Gascón-Giménez, Antonio García-Merino, Lluís Ramió-Torrentà
Publikováno v:
Multiple Sclerosis and Related Disorders. 50:102860
Background Primary progressive multiple sclerosis (PPMS) has long been defined by progressive disability accrual in the absence of initial relapses. However, its underlying neurodegenerative process seems to be accompanied by central nervous system i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07849d7d5dbc4200926e8be3d8716cd8
https://doi.org/10.1016/j.msard.2021.102860
https://doi.org/10.1016/j.msard.2021.102860
Autor:
Inés González-Suárez, Pedro Sánchez, Guillermo Izquierdo, C Iñiguez, Eulalia Rodríguez-Martín, Lucienne Costa-Frossard, Luisa M. Villar, Yolanda Blanco, Noelia Villarrubia, Jose Ignacio Fernández-Velasco, Luis Brieva, Yolanda Aladro, Ester Carreón-Guarnizo, Luis A. Rodríguez de Antonio, Jaime Masjuan, Enric Monreal, Aleksandra Maceski, José Meca-Lallana, Susana Sainz de la Maza, Francisco Gascón-Giménez, Albert Saiz, Jens Kuhle, Ernesto Roldán, Paulette Esperanza Walo-Delgado, Virginia Meca-Lallana
Publikováno v:
Neurology® Neuroimmunology & Neuroinflammation
article-version (Version of Record) 3
article-version (Version of Record) 3
ObjectiveTo analyze the changes induced by ocrelizumab in blood immune cells of patients with primary progressive MS (PPMS).MethodsIn this multicenter prospective study including 53 patients with PPMS who initiated ocrelizumab treatment, we determine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2beed1a6ce41ad6998538ba01584f1c9
https://doi.org/10.1212/nxi.0000000000000940
https://doi.org/10.1212/nxi.0000000000000940
Rituximab para el tratamiento de la miastenia grave generalizada: experiencia en la práctica clínica
Autor:
Elena Martínez Monte, Francisco Gascón Giménez, José Andrés Domínguez Morán, José Miguel Láinez Andres
Publikováno v:
Revista de Neurología. 73:416
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a417218a506ea46a131f5c29465549a
https://doi.org/10.33588/rn.7312.2021166
https://doi.org/10.33588/rn.7312.2021166
Autor:
Sara Gil-Perotin, Jessica Castillo-Villalba, Francisco Pérez-Miralles, Nicolás Medrano, Francisco Gascón-Giménez, Bonaventura Casanova, Jorge Maurino, Daniel Prefasi, Rocío Gómez-Ballesteros, A. García-Merino, Laura Cubas, Carmen Alcalá, Esther Álvarez-García
Publikováno v:
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
Neurology® Neuroimmunology & Neuroinflammation
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
Neurology® Neuroimmunology & Neuroinflammation
ObjectiveTo assess the role of CSF chitinase 3-like-1 (CHI3L1), chitinase 3-like-2 (CHI3L2), and neurofilament light chain (NfL) in predicting the course of primary progressive MS (PPMS).MethodsWe analyzed CSF CHI3L1, CHI3L2, and NfL levels in 25 pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76bcae7ae9187017db95f038f0839254
https://doi.org/10.1212/nxi.0000000000000815
https://doi.org/10.1212/nxi.0000000000000815